Related Experiment Video
Updated: May 16, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Joanne Bowes1, Andrew J Brown, Jacques Hamon
1AstraZeneca R&D, Alderley Park, Cheshire SK10 4TG, UK. Joanne.Bowes@astrazeneca.com
Abstract:
In vitro pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
In Vitro Drug Release Testing: Overview, Development and Validation
Clinically Relevant Drug Product Specifications: Methods of Establishment
Preclinical Development: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacogenetics of Drug Metabolism: Overview
